ST. LOUIS, Sept. 09, 2024 (GLOBE NEWSWIRE) — Stereotaxis STXS, a pioneer and international chief in surgical robotics for minimally invasive endovascular intervention, at present introduced that David Fischel, Chairman and CEO, will characterize Stereotaxis at two upcoming investor conferences.
“We respect the chance to take part in these conferences and look ahead to sharing Stereotaxis’ continued technological, industrial and strategic progress,” says Mr. Fischel. One-on-one conferences with Mr. Fischel could be organized by means of registration with the conferences.
About Stereotaxis
Stereotaxis STXS is a pioneer and international chief in revolutionary surgical robotics for minimally invasive endovascular intervention. Its mission is the invention, improvement and supply of robotic methods, devices, and data options for the interventional laboratory. These improvements assist physicians present unsurpassed affected person care with robotic precision and security, increase entry to minimally invasive remedy, and improve the productiveness, connectivity, and intelligence within the working room. Stereotaxis expertise has been used to deal with over 100,000 sufferers throughout america, Europe, Asia, and elsewhere. For extra data, please go to www.stereotaxis.com.
This press launch contains statements which will represent “forward-looking” statements, normally containing the phrases “imagine”, “estimate”, “undertaking”, “count on” or related expressions. Ahead-looking statements inherently contain dangers and uncertainties that might trigger precise outcomes to vary materially. Elements that may trigger or contribute to such variations embrace, however will not be restricted to, the Firm’s skill to handle bills at sustainable ranges, acceptance of the Firm’s merchandise within the market, the impact of world financial circumstances on the flexibility and willingness of shoppers to buy its expertise, aggressive components, adjustments ensuing from healthcare coverage, dependence upon third-party distributors, timing of regulatory approvals, the influence of pandemics or different disasters, and statements referring to our current acquisition of APT, together with any advantages anticipated from the acquisition, and different dangers mentioned within the Firm’s periodic and different filings with the Securities and Trade Fee. By making these forward-looking statements, the Firm undertakes no obligation to replace these statements for revisions or adjustments after the date of this launch. There could be no assurance that the Firm will acknowledge income associated to its buy orders and different commitments as a result of a few of these buy orders and different commitments are topic to contingencies which can be outdoors of the Firm’s management and could also be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Government Officer
Kimberly Peery
Chief Monetary Officer
314-678-6100
[email protected]
Market News and Data brought to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
